A newly published study of Natreon’s patented PrimaVie shilajit shows the benefits of PrimaVie supplementation in maintaining muscular strength and hydroxyproline levels in recreationally active men. This study marks the ninth clinical trial on PrimaVie and is published in the January 2019 edition of The Journal of the International Society of Sports Nutrition by sport nutrition researchers from the University of Nebraska-Lincoln, Dr. Joshua Keller and Dr. Terry Housh. 
 
PrimaVie shilajit expands on a rich history of use of shilajit in Ayurveda by investing in modern science, clinical efficacy and nutrient standardization to achieve a profile consisting of urolithins, fulvic acid, and micro-minerals. In addition, GRAS affirmed PrimaVie is the only organic and Non-GMO project verified shilajit extract on the market. 
 
This U.S. based study, conducted at The University of Nebraska-Lincoln, was an eight-week, randomized, double-blind, placebo-controlled, clinical trial to examine the impact of PrimaVie on fatigue-induced percent decline in strength, and concentric peak torque and hydroxyproline levels. Subjects were all recreationally active, healthy males randomized to receive PrimaVie at 500 mg/day, 250 mg/day or a placebo. In summary, the results of the study demonstrated that eight weeks of PrimaVie shilajit supplementation at 500mg promoted the retention of muscular strength following the fatiguing protocol and decreased baseline hydroxyproline, which is a marker for collagen degradation. This suggested that the group supplementing with 500mg of PrimaVie shilajit was more resistant to fatigue and retained a greater level of maximal muscular strength. 
 
“The results of our study demonstrated the robust, positive effects of PrimaVie shilajit on important aspects of Sports Nutrition including strength, fatigue, and the maintenance of collagen health,” said Dr. Terry J. Housh, professor, and director of the Human Performance Laboratory, Department of Nutrition and Health Sciences, University of Nebraska-Lincoln. 
 
Prior to the UNL trial, Natreon had conducted eight clinical studies on PrimaVie to unlock the full potential of this important Ayurvedic nutrient. 
 
“We are very excited about these results of from the University of Nebraska-Lincoln (UNL) as this enhances our growing body of research highlighting PrimaVie’s role in collagen support. Our previous clinical studies at Ohio State University discovered that PrimaVie upregulates collagen and other extracellular matrix protein genes synergistically with exercise. Furthermore, the UNL study results show PrimaVie supplementation decreases degradation of collagen in the body as evidenced by decreases in hydroxyproline. These are significant findings because it shows that PrimaVie can work two ways to enhance collagen in the body and additionally it upregulates other extracellular matrix protein genes,” said Dr. Sanni Raju, CEO of Natreon. 
 
The new study reaffirms PrimaVie’s use in sports performance products and expands its benefits into healthy aging and strength by demonstrating a reduction in hydroxyproline (a marker of collagen degradation) along with increases in strength in athletic males.
 
“Sports Nutrition is a primary focus for Natreon and PrimaVie is our lead ingredient in the category given its historical use as an adaptogen for energy. PrimaVie’s historical use in Ayurveda, positive clinical trial results, natural, botanical, organic and non-GMO project verified attributes, clearly differentiates PrimaVie from other ingredients in the market,” said Bruce Brown, president of Natreon.